Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
Execs On The Move: Bausch & Lomb And Stille Both Appoint New CEOs In March
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
More from Leadership
• By
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.
• By
Among early cancer screening tests, SpotitEarly stands out by combining dogs’ superior sense of smell with machine learning. SpotitEarly plans two US clinical trials for breast and lung cancer aiming to seek FDA clearance, but needs more funding to support clinical development and commercialization.
More from Medtech Insight
• By
BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
• By
Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.